Thus, the inhibition of the observed AMD‐like pathologies in VEGF‐Ahyper mice by targeting caspase‐1/caspase‐11 is supported by the functional assessment of visual function (ERGs) and by clinical imaging techniques (OCTs and fundus imaging) in these mice. The gene discussed is VEGFA; the disease is age-related macular degeneration.